A randomised phase II/III study in Waldenströms macroglobulinaemia (WM) has opened to recruitment in the UK. The RAINBOW study is run by the CR UK & UCL Cancer Trials Centre and is supported by Janssen-Cilag Ltd.
Waldenström's macroglobulinaemia (WM) is a slow-growing type of non-Hodgkin lymphoma which affects certain white blood cells. The RAINBOW study will be assessing ‘chemotherapy free’ treatment as primary therapy for WM. Researchers are looking to find out whether this can potentially improve response outcome and durability, and, importantly, reduce toxicity for WM patients.
The study will collect information and samples from at least 148 patients over the next 4 years. Patients who take part in the trial will receive the drug ibrutinib in combination with rituximab or a combination of dexamethasone, rituximab and cyclophosphamide.
RAINBOW will be run at 50 hospitals in the UK. There is more information about the RAINBOW trial
on the UCL CTC website.